The company has not filed an annual or quarterly report since its Q3 FY2019 10-Q, filed Oct 30, 2019. Its latest SEC filing is a SC 13G/A from Feb 17, 2021.
10-Q for Q3 FY2019, filed Oct 30, 2019
The sections below describe the company as of the FY2018 annual report.
Develops small-molecule drug candidates for people with cancer and rare diseases, targeting groups identified by biological markers.
10-K for FY2018, filed Mar 7, 2019
Pharmaceutical and biotechnology companies, research institutions, and independent investigators work with ArQule through collaborations; it also licenses drug candidates to development partners.
10-K for FY2018, filed Mar 7, 2019
10-K for FY2018, filed Mar 7, 2019
Revenue from one customer represented approximately 72% of total revenue during 2018 and revenue from another customer represented…View ↗
10-Q for Q3 FY2019, filed Oct 30, 2019
−$10.7MView ↗
8-K, filed Jan 16, 2020
As a result of the consummation of the Offer and the Merger, there was a change in control of ArQule, and Merck, as the direct parent of…View ↗
8-K, filed Dec 9, 2019
Pursuant to the Merger Agreement, upon the terms and subject to the conditions thereof, Merger Sub will merge with and into ArQule, with…View ↗
8-K, filed Oct 30, 2019
For 2019, ArQule expects revenue to range between $2 and $5 million. Net loss is expected to range between $40 and $43 million, and net…View ↗
8-K, filed Mar 15, 2019
(b) On March 15, 2019, ArQule, Inc. (the “Company”) announced that Robert J. Weiskopf, the Company’s Senior Vice President, Chief Financial…View ↗
Pipeline focus
The older report centered its business overview on tivantinib and worldwide development partners; the latest describes BTK and AKT drug candidates and derazantinib, with derazantinib licensed to development partners.
10-K for FY2015, filed Feb 29, 2016 10-K for FY2018, filed Mar 7, 2019ARQ 531 is a potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK) that is in Phase 1…View ↗
Miransertib (ARQ 092) is a potent and selective inhibitor of protein kinase B (AKT), a serine/threonine kinase. We expect to commence a…View ↗
ARQ 751 is a next-generation, highly potent and selective inhibitor of AKT that is in Phase 1 clinical development for solid tumors…View ↗
Derazantinib (ARQ 087) is a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family…View ↗
Competes with AbbVie, Amgen, Astellas Pharma, Array BioPharma, AstraZeneca, Celgene, Curis, Exelixis, Eli Lilly, Gilead Sciences, GlaxoSmithKline, Incyte, Infinity Pharmaceuticals, Johnson and Johnson, Merck, Merck KGaA, Novartis, Pfizer, Principia Biopharma, and Roche Group
10-K for FY2018, filed Mar 7, 2019In the area of small molecule anti-cancer therapeutics, we have identified a number of companies that have clinical development programs…View ↗
Loading...
